News & Updates
Showing Multidisciplinary articles
Showing
Does atezolizumab improve OS in patients with resected NSCLC and PD-L1 ≥1 percent?
The first interim analysis of the phase III IMpower010 trial suggests an overall survival (OS) benefit with atezolizumab compared with best supportive care (BSC) in patients with resected non-small cell lung cancer (NSCLC) with PD-L1* tumour cell expression ≥1 percent.
Does atezolizumab improve OS in patients with resected NSCLC and PD-L1 ≥1 percent?
16 Oct 2022
Anti-TNF continuation after pregnancy prevents relapse in women with IBD
Treatment continuation with antitumour necrosis factor (anti-TNF) after 24 weeks of pregnancy seems to provide benefits in terms of inflammatory bowel disease (IBD) activity and prematurity without affecting neonatal outcomes and serious infections in newborns, reports a study.
Anti-TNF continuation after pregnancy prevents relapse in women with IBD
16 Oct 2022
Skipping meal tied to increased fat deposition in type 2 diabetes
Among patients with type 2 diabetes (T2D), those who eat two meals per day exhibit higher greater intrapancreatic fat deposition than those who consume three meals per day, a study has found.
Skipping meal tied to increased fat deposition in type 2 diabetes
15 Oct 2022
Skin type factors in dupilumab efficacy in atopic dermatitis
The use of dupilumab in the treatment of atopic dermatitis appears to benefit patients who have dark skin types more than those who have light skin types, as shown in a study.
Skin type factors in dupilumab efficacy in atopic dermatitis
15 Oct 2022
Sigmoidoscopy screening offers 15-year benefit in CRC incidence, mortality
Sigmoidoscopy screening provides a significant and sustained effect on colorectal cancer (CRC) incidence and mortality for 15 years, according to a pooled analysis of randomized trials.
Sigmoidoscopy screening offers 15-year benefit in CRC incidence, mortality
15 Oct 2022
First-line SGLT2 inhibitors, GLP1 receptor agonists need to cut price to be cost-effective
First-line treatment with sodium–glucose cotransporter-2 (SGLT2) inhibitors or glucagon-like peptide-1 (GLP1) receptor agonists improves outcomes in patients with type 2 diabetes (T2D), but to be cost-effective, the prices of these drugs must drop by at least 70 percent, suggests a study.
First-line SGLT2 inhibitors, GLP1 receptor agonists need to cut price to be cost-effective
15 Oct 2022
Pemetrexed-based chemo boosts survival in NSCLC
As an add-on to gefitinib monotherapy, pemetrexed-based chemotherapy improves survival outcomes in nonsmall cell lung cancer (NSCLC) patients harbouring EGFR mutations, a recent study has found.
